Patents by Inventor Hanne Everland
Hanne Everland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10123908Abstract: The present invention relates to method of preparing an absorbent wound care device comprising an active agent on a wound contacting surface, such as e.g. a protein or an enzyme, by the use of electrospraying, and a wound care device obtained by said method. The invention further relates to a wound care device comprising Thrombin and a polyurethane foam, and a method of treating bleeding.Type: GrantFiled: July 10, 2012Date of Patent: November 13, 2018Assignee: Coloplast A/SInventors: Hanne Everland, Kurt Osther, Jacob Vange, Lene Feldskov Nielsen
-
Patent number: 9636438Abstract: The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell morphology and distribution.Type: GrantFiled: March 7, 2008Date of Patent: May 2, 2017Assignee: Coloplast A/SInventors: Lene Feldskov Nielsen, Jens Hoeg Truelsen, Hanne Everland
-
Patent number: 9295762Abstract: The present application discloses that incorporation of dermatan sulfate and/or HA in composite scaffolds of certain polymers gives rise to a chondrogenic effect on chondrocytes resulting in formation of cartilage that resembles the natural ECM. This effect with dermatan sulfate as the primary additive has not previously been seen. The composites are formed by incorporation of dermatan sulfate finely dispersed particles optionally nanoparticles or as molecular dissolutions in a polymer matrix with no bonding between the DS and the matrix, providing the DS to the chondrocytes in an accessible non-crosslinked form.Type: GrantFiled: March 7, 2008Date of Patent: March 29, 2016Assignee: Coloplast A/SInventors: Hanne Everland, Jacob Vange, Christian Clausen, Lene Feldskov Nielsen
-
Patent number: 9155662Abstract: The formation of a non-woven, free from organic solvent, formed through parallel formation of fibers on a collection device is disclosed. As the individual fibers are dry prior to contact with other fibers, the different contents of the various fiber types do not interact. However, when wetted, the fibers will start to be dissolved, or swell, and the different contents will be released and then interact. For the example of thrombin and fibrinogen, the interaction will initiate the formation of a fibrin coagulum by the cleavage of fibrinogen through the action of thrombin to form fibrin monomers that spontaneously polymerize to form a three dimensional network of fibrin.Type: GrantFiled: March 1, 2013Date of Patent: October 13, 2015Assignee: Coloplast A/SInventors: Jens Hassingboe, Jacob Vange, Hanne Everland, Rong Weimin
-
Patent number: 9101681Abstract: The present application discloses an alternative method for the formation of non-woven with fibers in the 1 to 200 ?m range. Using an aqueous solution of gelatin (optionally with <30% of low molecular weight alcohol) the fibers are ejected utilizing pressurized air emitted from nozzle and the non-woven formed directly from the emitted thin fibers. The gelatin non-woven can be cross-linked by heat-treatment or chemical cross-linking, and the non-woven is biocompatible as measured by fibroblast growth in vitro and wound healing on pigs in vivo.Type: GrantFiled: April 11, 2014Date of Patent: August 11, 2015Assignee: Coloplast A/SInventors: Jens Hassingboe, Jakob Vange, Hanne Everland
-
Publication number: 20150017862Abstract: The present application discloses an alternative method for the formation of non-woven with fibers in the 1 to 200 ?m range. Using an aqueous solution of gelatin (optionally with <30% of low molecular weight alcohol) the fibers are ejected utilizing pressurized air emitted from nozzle and the non-woven formed directly from the emitted thin fibers. The gelatin non-woven can be cross-linked by heat-treatment or chemical cross-linking, and the non-woven is biocompatible as measured by fibroblast growth in vitro and wound healing on pigs in vivo.Type: ApplicationFiled: April 11, 2014Publication date: January 15, 2015Applicant: Coloplast A/SInventors: Jens Hassingboe, Jakob Vange, Hanne Everland
-
Patent number: 8877246Abstract: The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive.Type: GrantFiled: January 11, 2013Date of Patent: November 4, 2014Assignee: Coloplast A/SInventors: Hanne Everland, Peter Samuelsen, Jakob Vange, Christian Clausen, Monica Ramos Gallego
-
Patent number: 8877223Abstract: The present application discloses biodegradable polymers, to porous and other materials comprising such polymers, and to various medical uses of such materials, including use as a scaffold for supporting cell adhesion or the in-growth for regeneration of tissue. The polymer is of the formula A-O—(CHR1CHR2O)n—B wherein A is a poly(lactide-co-glycolide) residue, the molar ratio of (i) lactide units [—CH(CH3)—COO—] and (ii) glycolide units [—CH2—COO—] in the poly(lactide-co-glycolide) residue being in the range of 80:20 to 10:90, B is either a poly(lactide-co-glycolide) residue or hydrogen, C1-6-alkyl or hydroxy protecting groups, one of R1 and R2 is hydrogen or methyl, and the other is hydrogen, n is 10-1000, the molar ratio of (iii) polyalkylene glycol units [—(CHR1CHR2O)—] to the combined amount of (i) lactide units and (ii) glycolide units in the poly(lactide-co-glycolide) residue(s) is at the most 14:86, and the molecular weight of the copolymer is at least 20,000 g/mol.Type: GrantFiled: March 7, 2007Date of Patent: November 4, 2014Assignee: Coloplast A/SInventors: Jakob Vange, Khadija Schwach-Abdellaoui, Hanne Everland, Peter Sylvest Nielsen, Brian Nielsen, Lene Karin Jespersen, Lene Feldskov Nielsen
-
Publication number: 20140248420Abstract: The present invention relates to method of preparing an absorbent wound care device comprising an active agent on a wound contacting surface, such as e.g. a protein or an enzyme, by the use of electrospraying, and a wound care device obtained by said method. The invention further relates to a wound care device comprising Thrombin and a polyurethane foam, and a method of treating bleeding.Type: ApplicationFiled: July 10, 2012Publication date: September 4, 2014Applicant: Coloplast A/SInventors: Hanne Everland, Kurt Osther, Jacob Vange, Lene Feldskov Nielsen
-
Patent number: 8753672Abstract: The present application discloses an alternative method for the formation of non-woven with fibers in the 1 to 200 ?m range. Using an aqueous solution of gelatin (optionally with <30% of low molecular weight alcohol) the fibers are ejected utilizing pressurized air emitted from nozzle and the non-woven formed directly from the emitted thin fibers. The gelatin non-woven can be cross-linked by heat-treatment or chemical cross-linking, and the non-woven is biocompatible as measured by fibroblast growth in vitro and wound healing on pigs in vivo.Type: GrantFiled: April 24, 2007Date of Patent: June 17, 2014Assignee: Coloplast A/SInventors: Jens Hassingboe, Jakob Vange, Hanne Everland
-
Publication number: 20130251758Abstract: The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive.Type: ApplicationFiled: January 11, 2013Publication date: September 26, 2013Applicant: COLOPLASTInventors: HANNE EVERLAND, PETER SAMUELSEN, JAKOB VANGE, CHRISTIAN CLAUSEN, MONICA RAMOS GALLEGO
-
Publication number: 20120165957Abstract: The present invention relates to new reinforced biodegradable scaffolds for soft tissue regeneration, as well as methods for support and for augmentation and regeneration of living tissue, wherein a reinforced biodegradable scaffold is used for the treatment of indications, where increased strength and stability is required besides the need for regeneration of living tissue within a patient. The present invention further relates to the use of scaffolds together with cells or tissue explants for soft tissue regeneration, such as in the treatment of a medical prolapse, such as rectal or pelvic organ prolapse, or hernia.Type: ApplicationFiled: July 6, 2010Publication date: June 28, 2012Inventors: Hanne Everland, Lene Feldskov Nielsen, Jakob Vange, Monica Ramos Gallego
-
Patent number: 8053559Abstract: We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration is equally distributed in the dressing hence avoiding unnecessary high concentrations of ECM. In addition to the effect of the ECM, the porous structure of the base material provides the cells with a structure for in-growth.Type: GrantFiled: October 26, 2006Date of Patent: November 8, 2011Assignee: Coloplast A/SInventors: Peter Sylvest Nielsen, Brian Nielsen, Lene Karin Jespersen, Hanne Everland, Lene Feldskov Nielsen
-
Publication number: 20110014267Abstract: An isolated, acellular biosynthetic cartilaginous matrix substantially devoid of synthetic biodegradable scaffold structure is provided. Through a method with the steps of a) contacting in vitro a population of chondrogenic cells with a synthetic biodegradable scaffold; b) culturing in vitro for a period of time said chondrogenic cells within said synthetic biodegradable scaffold so that the chondrogenic cells produce a biosynthetic cartilaginous matrix; c) substantially removing any antigen derived from said chondrogenic cells a matrix suitable of implantation into a living individual mammal, such as a human being is obtained.Type: ApplicationFiled: March 2, 2009Publication date: January 20, 2011Inventors: Hanne Everland, Peter Samuelsen, Jakob Vange, Christian Clausen
-
Publication number: 20100322908Abstract: The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive.Type: ApplicationFiled: March 2, 2009Publication date: December 23, 2010Inventors: Hanne Everland, Peter Samuelsen, Jakob Vange, Christian Clausen, Monica Ramos Gallego
-
Publication number: 20100239560Abstract: The formation of a non-woven, free from organic solvent, formed through parallel formation of fibers on a collection device is disclosed. As the individual fibers are dry prior to contact with other fibers, the different contents of the various fiber types do not interact. However, when wetted, the fibers will start to be dissolved, or swell, and the different contents will be released and then interact. For the example of thrombin and fibrinogen, the interaction will initiate the formation of a fibrin coagulum by the cleavage of fibrinogen through the action of thrombin to form fibrin monomers that spontaneously polymerize to form a three dimensional network of fibrin.Type: ApplicationFiled: April 17, 2008Publication date: September 23, 2010Inventors: Jens Hassingboe, Jacob Vange, Hanne Everland, Rong Weimin
-
Publication number: 20100086578Abstract: The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell morphology and distribution.Type: ApplicationFiled: March 7, 2008Publication date: April 8, 2010Inventors: Lene Feldskov Nielsen, Jens Hoeg Truelsen, Hanne Everland
-
Publication number: 20100087839Abstract: The present application discloses that incorporation of dermatan sulfate and/or HA in composite scaffolds of certain polymers gives rise to a chondrogenic effect on chondrocytes resulting in formation of cartilage that resembles the natural ECM. This effect with dermatan sulfate as the primary additive has not previously been seen. The composites are formed by incorporation of dermatan sulfate finely dispersed particles optionally nanoparticles or as molecular dissolutions in a polymer matrix with no bonding between the DS and the matrix, providing the DS to the chondrocytes in an accessible non-crosslinked form.Type: ApplicationFiled: March 7, 2008Publication date: April 8, 2010Inventors: Lene Feldskov Nielsen, Jens Truelsen, Hanne Everland
-
Publication number: 20100034868Abstract: The present application discloses that incorporation of dermatan sulfate and/or HA in composite scaffolds of certain polymers gives rise to a chondrogenic effect on chondrocytes resulting in formation of cartilage that resembles the natural ECM. This effect with dermatan sulfate as the primary additive has not previously been seen. The composites are formed by incorporation of dermatan sulfate finely dispersed particles optionally nanoparticles or as molecular dissolutions in a polymer matrix with no bonding between the DS and the matrix, providing the DS to the chondrocytes in an accessible non-crosslinked form.Type: ApplicationFiled: March 7, 2008Publication date: February 11, 2010Inventors: Hanne Everland, Jacob Vange, Christian Clausen, Nielsen Lene Feldskov
-
Publication number: 20090280154Abstract: We add discontinuous regions of Extra Cellular Matrix (ECM) to a biodegradable scaffold. Hereby it is possible to combine the range of physical properties the scaffold can offer with the reconstructive properties of the ECM. The optimal amount of discrete ECM material for each application is disclosed and this concentration is equally distributed in the dressing hence avoiding unnecessary high concentrations of ECM. In addition to the effect of the ECM, the porous structure of the base material provides the cells with a structure for in-growth.Type: ApplicationFiled: October 26, 2006Publication date: November 12, 2009Inventors: Peter Sylvest Nielsen, Brian Nielsen, Lene Karin Jespersen, Hanne Everland, Lene Feldskov Nielsen